ULTRASOUND NEUROMODULATION OF THE SPHENOPALATINE GANGLION

• US 20110190668A1
• Filed: 02/03/2011
• Published: 08/04/2011
• Est. Priority Date: 02/03/2010
• Status: Abandoned Application

• Current Assignee: David J. Mishelevich
• Original Assignee: David J. Mishelevich
• Inventors: Mishelevich, David J.
• Application Number:
  US13/020,016
• Publication Number:
  US 20110190668A1
• Time in Patent Office: Days
• US Class Current: 601/2
• CPC Class Codes: A61B 8/0808 for diagnosis of the brain
• CPC Class Codes: A61N 2007/0021 Neural system treatment
• CPC Class Codes: A61N 2007/0026 Stimulation of nerve tissue
• CPC Class Codes: A61N 2007/0073 using multiple frequencies
• CPC Class Codes: A61N 2007/0078 with multiple treatment transducers
• CPC Class Codes: A61N 2007/0095 by modifying an excitation signal
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092
• CPC Class Codes: A61N 7/02 Localised ultrasound hyperthermia hyperthermia in general A61F7/00

Abstract

Disclosed are methods and systems for non-invasive neuromodulation of the Sphenopalatine Ganglion and associated neural structures vidian nerve and/or sphenopalatine nerve using an ultrasound transducer to treat migraine and cluster headaches as well as other indications such as neurologic and psychiatric conditions. Treatment may be unilateral or bilateral.

Claims

1. A method of non-invasively neuromodulating the target Sphenopalatine Ganglion and associated structures using ultrasound stimulation, the method comprising:

aiming an ultrasound transducer at the target,

applying pulsed power to said ultrasound transducer via a control circuit thereby modulating the activity of the target,

whereby connected intracranial neural structures are neuromodulated.

2. The method of claim 1, wherein the plurality of control elements is selected from the group consisting of intensity, frequency, pulse duration, firing pattern, and phase/intensity relationships.

3. The method of claim 1, further comprising focusing the sound field of an ultrasound transducer at the target Sphenopalatine Ganglion and associated structures neuromodulating the activity of the target in a manner selected from the group of up-regulation, down-regulation.

4. The method of claim 1, wherein the acoustic ultrasound frequency is in the range of 0.3 MHz to 0.8 MHz.

5. The method of claim 1, where in the power applied is less than 60 mW/cm².

6. The method of claim 1, wherein the configuration of ultrasound power is selected from the group consisting of monophasic and biphasic.

7. The method of claim 1, wherein a stimulation frequency for of 300 Hz or lower is applied for inhibition of neural activity.

8. The method of claim 1, wherein the stimulation frequency for excitation is in the range of 500 Hz to 5 MHz for excitation of neural activity.

9. The method of claim 1, wherein the focus area of the pulsed ultrasound is 0.1 to 0.5 inches in diameter.

10. The method of claim 1, wherein the mechanism for focus of the ultrasound is selected from the group of fixed ultrasound array, flat ultrasound array with lens, non-flat ultrasound array with lens, flat ultrasound array with controlled phase and intensity relationships, and ultrasound non-flat array with controlled phase and intensity relationships.

11. The method of claim 1, wherein the neuromodulation of the Sphenopalatine Ganglion and related neural structures is selected from the group consisting of unilateral and bilateral.

12. The method of claim 1, wherein the neuromodulation results in a durable effect selected from the group consisting of Long-Term Potentiation and Long-Term Depression.

13. The method of claim 1, wherein the disorder treated is selected from the group consisting of headaches in various forms, migraine headaches in various forms, cluster headaches in various forms, neuralgias, other pain syndromes, movement and muscular disorders, epilepsy, hypertension, cerebral vascular disorders including stroke, autoimmune diseases, sleep disorders, asthma, metabolic disorders, addiction, autonomic disorders (including, but not limited to cardiovascular disorders, gastrointestinal disorders, genitourinary disorders), and neuropsychiatric disorders.

14. The method of claim 1 wherein ultrasound mediated modification is selected from the group consisting of the properties of the Blood-Brain Barrier and cerebral blood flow.

15. The method of claim 1, wherein ultrasound therapy is combined with one or more therapies selected from the group consisting of medications, electrical stimulation, local anesthetic blocks, surgical transection, surgical resection, radiofrequency, alcohol/phenol infiltration, radiosurgery, cryotherapy, medication, avoidance of triggers, diet modification, physical therapy, chiropractic manipulation, and acupuncture.